SCHEMBL3477801

SCHEMBL3477801

O=C(NCCc1ccccc1)Nc1[nH]c2ccc(Br)cc2c1S(=O)(=O)N1CCCC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NAMPT P43490 2/20 0.42
TSHR P16473 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
EPHX2 P34913 1/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 2/20 0.41
CXCR2 P25025 1/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3476809 0.95 KDM4E (0.41) ALDH1A1GAAKDM4EHTTNAMPT
SCHEMBL3476757 0.91 NAMPT (0.52) ALDH1A1GAAHTTNAMPTMAPT
SCHEMBL3478247 0.88 L3MBTL1 (0.41) ALDH1A1KDM4EHTTNAMPTL3MBTL1
SCHEMBL3477796 0.87 TSHR (0.49) ALDH1A1KDM4ETSHRPOLBMAPT
SCHEMBL3477114 0.85 MAPT (0.51) ALDH1A1KDM4EHPGDHTTNAMPT
SCHEMBL3477440 0.85 LMNA (0.43) ALDH1A1GAAHSD17B10MAPTSMN1; SMN2
SCHEMBL3477830 0.84 LMNA (0.41) GAAL3MBTL1MAPTCXCR2
SCHEMBL3476271 0.83 NAMPT (0.57) ALDH1A1GAANAMPTEPHX2MAPT
SCHEMBL3476335 0.83 NAMPT (0.45) ALDH1A1HTTNAMPTMAPTPKM
SCHEMBL3476880 0.83 KDM4E (0.41) ALDH1A1GAAKDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-15 US claimed
EP-1898927-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2008-03-19 EP claimed
WO-2007002481-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-01-04 WO claimed
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors RNGTT, RTF1, POLR1E ALDH1A1 1178/4885GAA 563/4885KDM4E 1660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.